0J4V Stock Chart & Stats
$0.49
$0.02(3.69%)
At close: 4:00 PM EDT
$0.49
$0.02(3.69%)
Day’s Range― - ―
52-Week Range$0.39 - $1.92
Previous CloseN/A
Volume393.00
Average Volume (3M)13.92K
Market Cap
$93.92M
Enterprise Value$249.64
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$141.63M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding189,279,370
10 Day Avg. Volume10,897
30 Day Avg. Volume13,919
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)15.12
Price to Sales (P/S)1.40
P/FCF Ratio-7.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside308.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$165.66M
Bulls Say, Bears Say
Bulls Say
ZYNRELEF Commercial MomentumSustained unit growth and a high-impact distributor program demonstrate scalable commercial execution. IGNITE-driven account expansion increases procedural penetration and recurring hospital usage, supporting durable revenue expansion and lower marginal selling costs over the next several quarters.
APONVIE Formulary And Guideline AdoptionBroad formulary access, a permanent product-specific J-code and top-tier guideline endorsement create structural reimbursement and clinical adoption advantages. These elements materially raise bar-to-entry for competitors and support predictable, procedure-driven demand across surgical settings.
CINVANTI Oncology Franchise StabilityA sizeable, stable NK1 market share and targeted reactivation program point to resilient oncology revenue. The combination of existing share and incremental account wins provides a repeatable revenue base that cushions overall cash generation while commercial execution continues.
Bears Say
High Leverage And Thin EquityExtremely low equity versus sizable debt constrains financial flexibility and elevates refinancing and dilution risk. Over a multi-month horizon this leverage can limit strategic options, increase interest burden sensitivity, and pressure management to pursue dilutive financing if cash needs persist.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow mean the business is not self-financing, increasing dependency on external capital. Over 2–6 months this raises execution risk for commercial investments and heightens potential for equity issuance or costly debt, pressuring long-term capital structure.
CINVANTI Patent Invalidation RiskA district court invalidation of key patents creates a clear pathway for generic entrants, threatening CINVANTI margins and market share. Even with an appeal, legal uncertainty and potential eventual generic competition pose a durable downside to oncology franchise revenue and long-term profit sustainability.
Heron Therapeutics News
0J4V FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest share price was $0.39 and its highest was $1.92 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $93.92M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is tomorrow.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on May 11, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.023 by -$0.017.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Heron Therapeutics dividends here
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is >-0.01.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 189,279,370 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.023. Following the earnings report the stock price went down -22.753%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Currently, no hedge funds are holding shares in GB:0J4V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (308.16% Upside)
$2.00 (308.16% Upside)
Blogger Sentiment
Neutral
GB:0J4V Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.44%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
0J4V Company Deck
0J4V Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call struck an overall positive tone: despite a weather-driven Q1 setback and temporary margin/EBITDA pressure, commercial momentum is clear across key products (ZYNRELEF, APONVIE, CINVANTI) with strong YoY demand growth, successful distributor incentive programs (IGNITE), clinical guideline endorsement for APONVIE, planned sales force expansions, and maintained full-year guidance. Management attributes most weaknesses to external, temporary factors and provided timelines for margin normalization and recovery, supporting confidence in achieving 2026 objectives.View all GB:0J4V earnings summaries0J4V Stock 12 Month Forecast
Average Price Target
$2.00
▲(308.16% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
Black Diamond Therapeutics
―
ADC Therapeutics
―
Gain Therapeutics
―